2 Results for "

2180923-05-9

" in MedChemExpress (MCE) Product Catalog:
Products (2)

2 Results for "2180923-05-9" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-129179
CAS No.: 2180923-05-9
Purity:  99.28%
Synonyms: APG-2575; Bcl-2/Bcl-xl inhibitor 1
Target:  

Bcl-2 Family Apoptosis

Research Areas:  

Cancer

Lisaftoclax is an orally active, selective BCL-2 inhibitor with a Ki of < 0.1 nM against human BCL-2. Lisaftoclax selectively binds to BCL-2, disrupts the BCL-2:BIM complex, and antagonizes the antiapoptotic function of BCL-2. Lisaftoclax induces BAX/BAK-dependent, caspase-mediated apoptosis, upregulates the pro-death proteins BIM and Noxa, and downregulates mitochondrial respiratory function and ATP production. Lisaftoclax can be used in the research of hematological malignancies including chronic lymphocytic leukemia, multiple myeloma, and diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-129179S
Synonyms: APG-2575-d8; Bcl-2/Bcl-xl inhibitor 1-d8
Target:  

Bcl-2 Family Apoptosis

Research Areas:  

Cancer

Lisaftoclax-d8 is the deuterated-labeled Lisaftoclax (HY-129179). Lisaftoclax is an orally active, selective BCL-2 inhibitor with a Ki of < 0.1 nM against human BCL-2. Lisaftoclax selectively binds to BCL-2, disrupts the BCL-2:BIM complex, and antagonizes the antiapoptotic function of BCL-2. Lisaftoclax induces BAX/BAK-dependent, caspase-mediated apoptosis, upregulates the pro-death proteins BIM and Noxa, and downregulates mitochondrial respiratory function and ATP production. Lisaftoclax can be used in the research of hematological malignancies including chronic lymphocytic leukemia, multiple myeloma, and diffuse large B-cell lymphoma .
loading...
    loading...